Thomas Burns has been appointed chief financial officer, XOMA Corp. He succeeds Fred Kurland who retires from his role as vice president, finance, chief financial officer and secretary, effective April 3, 2015. Mr. Burns will report to John Varian, chief executive officer.   “Fred has been an integral part of the team that has established XOMA as a leader in the discovery and development of therapeutic antibodies. He has ensured we have the capital we need to advance gevokizumab towards XO...